ASTRO, together with six other organizations, including the American Association of Physicists in Medicine (AAPM), American Nuclear Society (ANS), Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) and the Radiological Society of North America (RSNA), sent letters to the ranking members of the House Energy and Commerce Subcommittee on Energy, Climate and Grid Security, the Senate Environment and Public Works Committee, the House Appropriations Committee Subcommittee on Energy and Water Development and Related Agencies, and the Senate Appropriations Committee Subcommittee on Energy and Water Development opposing the Nuclear Medicine Clarification Act (HR 6815). If enacted, the bill would increase regulatory and financial burden without providing significant radiological or patient safety benefits by requiring that radiopharmaceutical extravasations be reported as medical events. Radiopharmaceutical extravasations are currently managed effectively by medical professionals and do not require additional regulatory burden.

Additionally, the NRC is currently in the rulemaking process related to medical event reporting for extravasations. The NRC's Advisory Committee on the Medical Use of Isotopes is holding a public meeting on June 17 to discuss the proposed rule package. The proposed rule package is expected to be made public later this year.